<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1499">
  <stage>Registered</stage>
  <submitdate>17/12/2003</submitdate>
  <approvaldate>17/12/2003</approvaldate>
  <actrnumber>ACTRN12606000370505</actrnumber>
  <trial_identification>
    <studytitle>A study of intravenous vinorelbine and oral capecitabine in patients with advanced breast cancer</studytitle>
    <scientifictitle>Phase II study of intravenous Vinorelbine (Navelbine) and Capecitabine (Xeloda) in patients with advanced breast cancer, assessing efficacy and toxicity</scientifictitle>
    <utrn />
    <trialacronym>NavXel, BC-03-02</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR440</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intravenous vinorelbine 25 mg/m2 day 1 and 8 and oral capecitabine 1000 mg/m2 days 1-14 every 21 days.  Maximum 9 cycles.</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary endpoint is efficacy.</outcome>
      <timepoint>Assessed by measuring response (tumour shrinkage) every 3 cycles using Response Evaluation Criteria in Solid Tumors (RECIST) criteria up to maximum of 9 cycles.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity</outcome>
      <timepoint>Each  cycle, up to max 9 cycles.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to progression</outcome>
      <timepoint>Every 3 months off treatment until progression/ death or loss to followup.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response</outcome>
      <timepoint>Every 3 months until progression/ death or loss to followup.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Every 3 months off treatment until death or loss to followup.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Advanced/ metastatic breast cancer; maximum of 1 prior chemotherapy for metastatic cancer; at lteat `1 measurable lesion by RECIST; &gt; 18 years; KPS &gt; 80%; adequate organ function</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Life expectance &lt;12 weeks; significant comorbidities; peripheral neuropathy &gt; grade1; other invasive cancers; unable to swallow pills whole</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>13/05/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr. Alison Davis, Dr Stephen Ackland</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Roche Australia</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pierre Fabre Australia/France</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Craig Lewis</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Francis Parnis</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Eugene Moylan</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Roche and Pierre Fabre</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial will determine the safety and activity of giving two new drugs together in women with advanced breast cancer.  Both of these drugs are active when given alone; giving them together may be better.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Canberra Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Calvary Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Prince of Wales Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Miserichordiae Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Ashford Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Alison Davis</name>
      <address>Medical Oncology Unit
The Canberra Hospital
PO Box 11
Woden ACT 2606</address>
      <phone>(02) 6244 2220</phone>
      <fax>(02) 6244 4266</fax>
      <email>alison.davis@act.gov.</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Alison Davis,</name>
      <address>Medical Oncology Unit
The Canberra Hospital
PO Box 11
Woden ACT 2606</address>
      <phone>(02) 6244 2220</phone>
      <fax>(02) 6244 4266</fax>
      <email>alison.davis@act.gov.</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>